Clinical trials
Breast Cancer Female clinical trials
Below are recruiting breast cancer female clinical trials, each written for real people, not researchers. We’re tracking 1,127 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06552091Recruiting
Digital self-hypnosis for hot flashes from hormone therapy
This trial tests a guided digital self-hypnosis program to help reduce hot flashes caused by hormone therapy for breast cancer. It aims to see if it can make hot flashes less frequent and bothersome.
Vandœuvre-lès-NancyAges 18 years+ - NCT05328258RecruitingPhase 3
Triptorelin to help protect fertility during cancer chemotherapy
This Phase 3 study tests whether a hormone medicine called triptorelin (a GnRH “fertility-protecting” medicine) can better protect ovarian function while you receive chemotherapy. The goal is to help preserve fertility and reduce the risk of early ovarian failure from cancer treatment.
GothenburgAges 14–42 - NCT06050109Recruiting
Continuing Ovarian Suppression After 5 Years
This trial checks if staying on ovarian function suppression (OFS) therapy beyond 5 years helps prevent breast cancer from coming back. It's for women with early-stage, hormone-sensitive (HR+ HER2-) breast cancer who have already completed 5 years of OFS.
Wuhan, HubeiAges 18–60 - NCT06336070Recruiting
Power training for metabolic health in postmenopausal cancer survivors
This trial compares two types of exercise—muscle power training and metabolic power training—to see which better improves your body's ability to use energy and control heart function. You may qualify if you are a postmenopausal woman who has had breast cancer and is not currently active.
Valencia, ValenciaAges 35–75 - NCT06498154RecruitingPhase 2
Skipping breast surgery for some patients after chemo
This trial tests whether women with certain aggressive breast cancers (HER2-positive without hormone receptors, or triple-negative) can safely skip breast surgery if chemotherapy makes their tumor completely disappear. The goal is to avoid surgery and its side effects when it may no longer be needed.
TianjinAges 18–70 - NCT06907810Recruiting
Study of fat molecules in long-term breast surgery pain
This trial looks at how certain natural fat molecules in your body might relate to long-term pain after breast cancer surgery. It could help doctors better understand and treat chronic pain in the future.
Brussels, Brussels CapitalAges 18 years+ - NCT07290153Recruiting
Psychological health and immunotherapy for TNBC
This study looks at how psychological factors and the immune system affect treatment response in women with triple-negative breast cancer. Researchers will use questionnaires and biological samples to understand these links.
Shanghai, Please SelectAges 18–70 - NCT06507618RecruitingPhase 3
Pre-surgery hormone therapy to guide radiation decisions for breast cancer
This trial tests whether taking hormone therapy for 3 months before breast-conserving surgery can help doctors decide if radiation is right for you. It is for women aged 65 and older with a common type of breast cancer that is hormone receptor-positive and HER2-negative.
New Haven, ConnecticutAges 65 years+ - NCT07151963Enrolling by invitation
Can brain stimulation reduce chemo nerve pain in breast cancer?
This study tests a gentle brain stimulation treatment (called theta burst) to see if it can reduce nerve pain caused by breast cancer chemotherapy. If you have ongoing tingling or burning in your hands or feet, this treatment aims to calm those symptoms without using more medication.
New Taipei CityAges 18–80 - NCT06673329RecruitingPhase 1
Brodalumab for immune-related side effects from cancer treatment
This trial tests if brodalumab, an antibody that blocks a specific immune pathway (IL-17), can help control side effects caused by immunotherapy cancer treatment. It is for people with advanced solid organ cancers who have immune-related side effects that are suspected to involve IL-17.
New York, New YorkAges 18 years+ - NCT06695845RecruitingPhase 2
Study of zanidatamab for HER2-positive solid tumors
This trial tests a drug called zanidatamab in people with advanced solid tumors that have high levels of HER2 protein (called HER2-positive). It aims to see if zanidatamab can shrink or slow the growth of these tumors.
Prescott, ArizonaAges 18 years+ - NCT07552467Recruiting
PET Imaging Scan for Detecting Cancer Using New Radioactive Tracer
This study tests a new type of imaging scan (PET/CT or PET/MR) that uses a radioactive tracer to help doctors better detect and diagnose various cancers. The scan targets a specific protein found in tumors, which may help identify cancer more accurately than standard imaging.
Wuhan, HubeiAges 18 years+ - NCT05461768RecruitingPhase 1
BL-M07D1 for HER2-positive or HER2-low breast cancer
This Phase 1 study tests BL-M07D1, a new investigational medicine, in people with HER2-positive or HER2-low breast cancer (and other solid tumors) that can’t be operated on or has spread. It aims to find a safe dose and learn how well the treatment may work based on HER2 levels in tumor tissue.
Fuzhou, FujianAges 18–75 - NCT06548919Recruiting
Treatment patterns for ESR1-mutated advanced breast cancer
This study looks at how Chinese patients with a specific gene change (ESR1 mutation) in ER-positive, HER2-negative advanced breast cancer are currently being treated. It will help doctors understand what treatments work best for people whose cancer has stopped responding to hormone therapy.
Suzhou, JiangsuAges 18 years+ - NCT06080620Recruiting
Choosing the best treatment for locally advanced breast cancer
This study looks at different treatment plans for women with newly diagnosed, locally advanced breast cancer (stage IIIb-IIIc). It aims to find the most effective combination of surgery, chemotherapy, and radiotherapy. If you are a woman aged 18-70 with this diagnosis and your tumor can be surgically removed, this trial may be an option for you.
BeijingAges 18–70 - NCT05635487RecruitingPhase 2
Neoadjuvant treatment for HER2-positive breast cancer with SHR-A1811
This trial tests whether SHR-A1811 alone, or together with pyrotinib, given before surgery, can shrink HER2-positive breast cancer. It may help you respond better to treatment while making surgery easier.
Shenyang, LiaoningAges 18–75 - NCT06435429RecruitingPhase 3
Zanidatamab vs trastuzumab for HER2+ breast cancer
This study compares a new drug called zanidatamab against trastuzumab (Herceptin), both given with a chemotherapy of your doctor's choice. It is for people with HER2-positive breast cancer that has spread and who have already tried T-DXd treatment.
Phoenix, ArizonaAges 18 years+ - NCT05704829RecruitingPhase 2
Trastuzumab-deruxtecan before surgery for HER2-positive early breast cancer
This trial compares giving trastuzumab-deruxtecan before surgery versus standard chemotherapy plus trastuzumab and pertuzumab. It aims to see which approach works better to shrink or control HER2-positive early breast cancer and improve outcomes.
Baden-Baden, Baden-WurttembergAges 18 years+ - NCT07136428RecruitingPhase 1/Phase 2
Asciminib for HER2+ breast cancer that has spread to the brain
This trial tests the drug asciminib for people with HER2-positive breast cancer that has spread to the brain and is growing. It may be an option if you have already tried standard treatments like T-DXd and tucatinib.
Durham, North CarolinaAges 18 years+ - NCT07389733RecruitingPhase 1/Phase 2
Study of HRS-6208 with other drugs for advanced breast cancer
This trial tests a new combination of drugs (HRS-6208 with HRS-8080, fulvestrant, or letrozole) for people with advanced or metastatic breast cancer that cannot be removed by surgery. It aims to see if these combinations can help shrink or slow the cancer.
Dalian, LiaoningAges 18–75 - NCT07235176RecruitingPhase 1/Phase 2
QLS1304 plus hormone therapy for ER+ breast cancer
This trial tests a new drug called QLS1304 combined with hormone therapy for people with ER-positive, HER2-negative breast cancer that has spread or come back and no longer responds to hormone therapy alone. The goal is to see if this combination can help shrink tumors or slow the disease.
ShanghaiAges 18 years+ - NCT07441460RecruitingPhase 3
KN026 plus HB1801 after surgery for HER2-positive breast cancer
This trial tests a combination of two drugs (KN026 and HB1801) given after surgery to prevent breast cancer from coming back in people with HER2-positive breast cancer that had spread to lymph nodes. It aims to improve cure rates with a targeted approach.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07047365RecruitingPhase 3
New drug for HER2-positive advanced breast cancer
This trial tests a new medicine called TQB2930 for people with advanced breast cancer that is HER2-positive. It is for those who have already had at least two prior anti-HER2 treatments and are willing to also receive chemotherapy chosen by their doctor.
Bengbu, AnhuiAges 18–75 - NCT07396324RecruitingPhase 2
A new drug before surgery for HR+ HER2- breast cancer
This trial tests whether the drug QL1706, given before surgery, can help treat hormone receptor positive and HER2-negative breast cancer. It is for people who have not yet had cancer spread to other parts of the body.
ShanghaiAges 18 years+
Hear when a new Breast Cancer Female trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for breast cancer female?
- Yes. Clin2 currently lists 1,127 recruiting breast cancer female studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a breast cancer female trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a breast cancer female trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.